Wave of New Innovation in Product Launches at the Wearable Technology Show
Leading the charge for future emerging connected technology, exhibitors at this year’s Wearable Technology Show will be showcasing some of the hottest and most innovative new products and prototypes of the year.
100 exhibitors from more than 20 countries will be on the show floor to unveil their latest innovations in smart technology, many of which will never have been seen before in Europe. Toshiba, WiTGrip and Thrive Wearables will all be exclusively be launching new launches and there will be over 20 others including:
- AIO Sleeve by KOMODO Technologies. A revolutionary, all-in-one wearable solution. From in depth activity tracking, to monitoring one’s overall health and wellness by using something KOMODO calls Health Score. The AIO App monitors unique heart rate patters and generates a score based on a five star system, all inside the comfort of a smart compression sleeve.
- ORA-C by Optinvent. The world’s first smart safety cap. A new type of wearable for professionals that uses a cutting edge patented AR display technology. Running on Android, Optinvent disrupts the smart glass experience with this new offering, that allows users to have an improved hands free, ergonomic experience. The ORA-C uses the company’s patented see-through retinal display, includes a microprocessor and a complete set of sensors.
- HearingFitness™ App by Oticon. The start of data-driven hearing care, the HearingFitness app gives insight into the daily use of the world’d first internet-connected hearing aids, Opn by Oticon. Using the app enables a more personalised hearing care than ever before, as it continually optimises a user’s solution to their specific, individual and changing needs and sound environments.
- INA by Savor Health. Intelligent Nutrition Assistant is developed by a team of data-scientists and oncology-credentialed medical professionals specifically for cancer patients. Designed to improve clinical and quality of life outcomes and empowers patients to take control of their disease.
This year’s Wearable Technology Show will also boast a diverse 200-strong speaker conference programme with contributions from some of the biggest names in wearables, digital health, AVR and IoT, including Microsoft, Samsung, HTC, Sky, Toshiba, NHS, Hugo Boss and Stella McCartney plus many more. The full conference programme can be viewed here: http://www.wearabletechnologyshow.net/conference
“Attendees are always drawn to the show by the expanse of new innovation we have on the ground to announce and demonstrate. This year, that will be no exception. There will be a vast range of new products on show from a wide cross section of industry sectors; health to business, and lifestyle to leisure, there’ll be something for everybody.” commented COO John Weir.
He added: “The show is a great platform for brands big and small to exhibit the best that smart technology has to offer. From start ups to household names, we can expect some exciting products and prototypes to be here. Coupled with our speaker conference programme, delegates can expect to garner insight to some of the latest innovation and how that’s shaping the technology of tomorrow.”
Organisers are expecting 5,000 attendees at the Wearable Technology Show next month, which takes place on 13-14 March at ExCeL London and is co-located with the AVR 360 Show, IOT Connect and the Digital Health Technology Show, making it Europe’s biggest launch event for emerging connected technology.
Register for your media pass here: http://www.wearabletechnologyshow.net/press-registration
Notes to editors:
About Wearable Technology Show
The Wearable Technology Show is Europe’s biggest launch event for emerging connected technology. Over 6,000 are expected to attend this year’s event – the fifth - to hear from some of the top names in wearables, digital health, AR/VR, and IOT. The Wearable Technology Show is co-located with the Digital Health Technology Show, AVR360 Show & IOT Connect.
For more information: www.wearabletechnologyshow.net /@wearabletecshow #WTS2018
Press can register for the show at http://www.wearabletechnologyshow.net/press-registration
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 15:00:00 EET | Tiedote
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre
Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 14:30:00 EET | Tiedote
Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos
Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 13:45:00 EET | Tiedote
Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b
Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 13:00:00 EET | Tiedote
Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its
Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma20.3.2019 13:00:00 EET | Tiedote
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. The project is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK. The Chief Investigator for the Phase 2 multi-center, 52-week trial is Professor Salman Siddiqui, Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals. Dexpramipexole is an orally available small molecule shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chr
SmartStream Partners with Cassini Systems to Help Firms Meet Uncleared Initial Margin Obligations20.3.2019 12:00:00 EET | Tiedote
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced its partnership with Cassini Systems, the leading provider of pre and post trade margin analytics for buy side derivatives trading, to help financial institutions comply with BCBS-IOSCO margin requirements for uncleared OTC derivatives. BCBS-IOSCO defines rules for margin requirements on Uncleared Over-the-Counter (OTC) derivatives known as Uncleared Margin Rules (UMR). ISDA has developed a Standard Initial Margin Model (SIMM) that can be used by market participants to provide a transparent and standardised margin methodology of bi-lateral trades. The roll out of UMR rules has now reached the buy side with phase 4 firms coming into scope in September 2019, and phase 5 firms in September 2020. SmartStream’s TLM Collateral Management provides firms with automated data management to reduce operational risks associated with collateral management. This partnership will integra
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme